A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC)
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2019
At a glance
- Drugs HTD 1801 (Primary)
- Indications Primary sclerosing cholangitis
- Focus Proof of concept; Therapeutic Use
- Sponsors HighTide Biopharma
- 17 Jan 2019 Planned End Date changed from 30 Apr 2019 to 3 Feb 2020.
- 17 Jan 2019 Planned primary completion date changed from 30 Nov 2018 to 12 Oct 2019.
- 12 Feb 2018 Status changed from not yet recruiting to recruiting.